Review Article: Targeting Peroxisome Proliferator‐Activated Receptors in Primary Biliary Cholangitis

20260 citationsJournal Articlehybrid Open Access

Authors

Jörn M. Schattenberg · Saarland University

Jesús M. Bañales · Biogipuzkoa Health Research Institute

Gideon Hirschfield · Toronto General Hospital

P. Trivedi · NIHR Birmingham Liver Biomedical Research Unit

Edward E. Cable · CymaBay Therapeutics (United States)

Charles A. McWherter · CymaBay Therapeutics (United States)

Andrew N. Billin

Abstract

Isoform selectivity contributes to the efficacy and safety profiles of PPAR agonists. Future research should investigate isoform-specific mechanisms, particularly regarding symptom relief and agent- and class-related toxicities.

Topics & Keywords

Peroxisome Proliferator-Activated Receptors Liver Diseases and Immunity Drug Transport and Resistance Mechanisms

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Alimentary Pharmacology & Therapeutics

DOI: 10.1111/apt.70598

Field-Weighted Citation Impact: 0.00